Remove DEA Remove Pharmaceutical Remove Safety
article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. Drug Enforcement Agency (DEA). This means that the medical and scientific communities can now celebrate broader access to research for the production of pharmaceutical products that are safer than smokable or vaporizable cannabis.

article thumbnail

Cannabis Litigation: Second Circuit Could Force DEA to Re- or Deschedule Marijuana

Canna Law Blog

Drug Enforcement Administration (DEA) when it comes to DEA’s handling of petitions to remove marijuana from the list of most dangerous drugs. Schedule I is reserved for drugs with a high potential for abuse, no currently accepted medical uses, and a lack of accepted safety for medical use.

DEA 108
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Veteran Health

Cannabis Law Report

–(BUSINESS WIRE)– CURE Pharmaceutical Holding Corp. Currently, CURE uses its Schedule 1 DEA license for the development of Cannabis (THC) oral film products and other psychoactive substances, and manufactures multiple commercial Cannabidiol (CBD) products in compliance with the 2018 U.S. OXNARD, Calif.–(BUSINESS

article thumbnail

DEA-Licensed Biopharmaceutical Research Company to Partner with CURE Pharmaceutical to Produce Federally-Compliant Cannabis-Based Medical Products

Cannabis Law Report

MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. BRC is a specialty pharmaceutical company that holds several DEA Registrations and is pioneering the federally legal cannabis space in the USA.

DEA 45
article thumbnail

The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?

Freedom Leaf

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51
article thumbnail

The Ketamine Clinic Craze: Legalities and Possibilities

Canna Law Blog

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. “ Off-label use ” (which is extremely common) is: the use of pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration.

Therapy 116
article thumbnail

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ is confident that their pharmaceutical drugs will bring much needed relief to patients suffering from the debilitating effects of Multiple Sclerosis and Huntington’s Disease.

DEA 51